UK
Tim Moore
I am the Global Business Development Lead for LCP Health Analytics.
With over 35 years of global leadership across biopharmaceutical operations, strategy, and consulting, I partner with large pharma and innovative biotech clients to translate complex challenges into patient-centered, commercially viable solutions.
Having worked as both a C-level pharma operator, as well as a strategic consultant, I can deeply appreciate and understand the realities and challenges our clients face.
My therapeutic expertise spans pulmonary, cardiometabolic, pain, gastrointestinal, cannabinoids, and orphan/rare diseases. I bring deep commercial strategy capabilities in, geographic market sequencing, biotech commercial planning, as well as business development/asset assessment.
Prior to LCP Health Analytics, I founded and scaled Indegene’s global biotech business, helping to guide Phase 2 biopharmas from asset to market. Previously, as Chief Commercial Officer at SYQE, I helped drive commercialization of a novel inhalation device platform. Earlier, I spent a decade in management consulting, including as Senior Partner and Global Life Sciences Lead at Capgemini Consulting. My career began at Pfizer, where I held progressive commercial and strategy roles.
I am driven by a singular goal: to be a transparent, trusted partner helping clients deliver innovative, accessible therapies that enable patients to live healthier, more productive lives.
Featured insights
Most Favored Nation clause: Why revising differential pricing may be wiser than importing global prices
Kevin Patterson, US Access Solutions, LCP and William Lob, Vice President, Strategic Initiatives PRMA, Indegene, discuss why the MFN clause may undermine US drug pricing sovereignty.
Reimagining patient support in the era of MFN: A strategic imperative for manufacturers
Lee Ann Steadman explores how the Most Favored Nation (MFN) policy is reshaping drug pricing and why manufacturers must reimagine patient support programs as strategic, sustainable models to protect access and deliver long-term value.
Achieving equitable representation in clinical trials
Matthew Hankins examines how integrating real-world evidence into diversity action plans can help clinical trial sponsors comply with FDA diversity guidance.
Investment Uncut: Kevin Patterson - Are pharma’s short-term pains a long-term opportunity?
In this podcast, our hosts are joined by Kevin Patterson to explore whether current challenges in the pharmaceutical sector could actually present a long-term investment opportunity.
